rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken
Aandeel

VIVORYON THERAPEUTICS N.V. NL00150002Q7

Laatste koers (eur)

1,936

  • Verschil

    -0,014 -0,72%

  • Volume

    18.186 Gem. (3M) 154,4K

  • Bied

    -  

  • Laat

    -  
+ In watchlist

Vivoryon is de naam. Daarom nieuw draadje

6.265 Posts
Pagina: «« 1 ... 293 294 295 296 297 ... 314 »» | Laatste | Omlaag ↓
  1. G(r)ijs 19 juli 2023 10:45

    • G(r)ijs

      Lid sinds: 02 aug 2022

      Laatste bezoek: 27 jan 2025

    • Aanbevelingen

      Ontvangen: 166

      Gegeven: 70

    •    Aantal posts: 317

    quote:

    fleurie schreef op 19 juli 2023 08:28:

    dit is toch niet door te spitten!!!!!!!!!
    je moet heel goed tussen alle non info door lezen inderdaad, maar dan zie je ook dat het meer tekst dan inhoud is :-)
  2. forum rang 5 Melkkoe APDS 28 juli 2023 19:08

    • Melkkoe APDS

      Lid sinds: 23 sep 2020

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 1282

      Gegeven: 50

    •    Aantal posts: 1.308

    quote:

    K. Wiebes schreef op 18 juli 2023 22:14:

    alzres.biomedcentral.com/articles/10....

    ..."In a phase 2a, ... study participants were treated with varoglutamstat in doses of 800?mg....
    Varoglutamstat showed an acceptable safety and tolerability profile in lower doses and with
    slower titration. The varoglutamstat-treatment group was also found to have a significant
    improvement of working memory"...
    Goed nieuws. Maar een officiële tussenstand komt Q1 2024 lees ik.
  5. forum rang 10 DeZwarteRidder 30 juli 2023 15:23

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 24059

      Gegeven: 10520

    •    Aantal posts: 101.952

    quote:

    K. Wiebes schreef op 30 juli 2023 12:08:

    pubmed.ncbi.nlm.nih.gov/34769222/
    www.alzforum.org/therapeutics/varoglu...
    Dat ziet er slecht voor Vivo en de patiënten:

    From March 2015 to April 2017, the Phase 2 SAPHIR trial compared a 12-week course of twice-daily 800 mg PQ912 tablets to placebo. It enrolled 120 people with MCI or mild dementia due to AD as ascertained by CSF Aß levels at screening. This trial took place in seven European countries. It met its primary outcome of safety, with no difference in the frequency of adverse events between the treatment and placebo arms. The treatment group had more skin reactions and gastrointestinal problems than placebo, and more discontinuations. PQ912 inhibited QC activity in CSF by 92 percent. It appeared to slightly decrease pyroglutamate Aß oligomers in CSF, though CSF Aß oligomers' concentrations are near the assay’s detection limit. The treatment group showed a benefit on working memory and a trend on attention, but no difference on five other neuropsychological tests. On EEG readings, the treatment group showed a reversal of AD-induced changes in theta and alpha rhythms. In CSF, the synaptic marker neurogranin and the inflammatory marker YKL40 trended downward from a known rise in AD. CSF AD biomarkers were unchanged (Jun 2017 news; Scheltens et al., 2018; Briels et al., 2020).
  6. forum rang 5 K. Wiebes 30 juli 2023 19:44

    • K. Wiebes

      Lid sinds: 13 sep 2007

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 1652

      Gegeven: 124

    •    Aantal posts: 5.578

    Daar hadden we 't al eens over gehad (kennelijk dus ook pech voor jou).

    Het is uiteraard nog geen gelopen race. Maar de bevindingen uit die vrij korte studie zijn mee-
    genomen in de opzet van de langere en omvangrijkere vervolgstudies (VIVIAD en VIVA-MIND).

    En mede omdat de FDA Donanemab géén versnelde goedkeuring wou geven wegens een te
    klein aantal patiënten met op z'n minst 12-maanden-data, heeft VIV recent de studieduur van
    hún studies verlengt; waardoor we nu dus moeten wachten tot Q1 v.w.b. data over de werking.

    mind.uci.edu/fda-decides-not-to-grant...,a%20person%20with%20Alzheimer's%20disease.

    Daarnaast is het zo, dat de werking én toxiciteit - tok-sissi; blijft wennen ;) - van Donanemab
    toenemen bij hogere doses. Als Varo helemaal niet werkt houdt het op; maar wanneer Varo
    onvoldóende zou werken, bestaat altijd nog de mogelijkheid die twee te combineren. Met het
    (vooralsnog) veiligere Varo erbij zou de dosis van Dona dan omlaag kunnen
  7. forum rang 4 HOBBYMAN 2 augustus 2023 16:46

    • HOBBYMAN

      Lid sinds: 22 feb 2019

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 659

      Gegeven: 34

    •    Aantal posts: 1.301

    Waarom forse daling vandaag, terwijl er volgens mij geen nieuws is. Of zou ook hier weer kapitaaluitbreiding gaan komen ten koste van aandeelhouders? ( conform Aptevo en Gaussin)
  8. forum rang 7 lucas D 2 augustus 2023 17:27

    • lucas D

      Lid sinds: 27 jun 2007

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 10614

      Gegeven: 8170

    •    Aantal posts: 30.877

    Vivoryon:

    2022:
    31 dec €10,320 = ijkpunt einde maand winst/verlies

    2023:
    31 januari slotkoers € 13,800 = + 36,8 %
    28 februari slotkoers € 14,420 = + 39,9 %
    31 maart slotkoers € 15,26 = + 49.9%
    30 april slotkoers € 13,520 = + 31 %
    31 mei slotkoers € 14,640 = + 41,9 %
    30 juni slotkoers € 12,340 = + 19,4 %
    31 juli slotkoers € 13,840 = + 34,2 %

    Slotkoers vrijdag 07 juli € 11,840
    Slotkoers vrijdag 14 juli € 12,260
    Slotkoers vrijdag 21 juli € 13,260
    Slotkoers vrijdag 28 juli € 13,320

    De maand juli een slotkoers van € 13,840 dat is € 1,500 hoger dan de voorgaande beursmaand.
    Nieuws:
    Blijft staan:

    De slotkoers van juli is € 3,520 hoger gesloten dan de slotkoers van 31 december 2022

    Hoogste dagkoers 05 mei € 19,480
    Laagste dagkoers 02 januari € 10,320
    Volgende maand een nieuw overzicht onder voorbehoud portefeuille.
  13. forum rang 7 lucas D 14 augustus 2023 12:39

    • lucas D

      Lid sinds: 27 jun 2007

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 10614

      Gegeven: 8170

    •    Aantal posts: 30.877

    Koers zakt langzaam maar zeker weg, niet voor het eerst in de zomertijd, vorig jaar ging de koers terug van € 23 naar € 7,20!
    En nu al van circa € 19,40 naar € 10,60 dagwaarde.
    De P:hase2 duurt ook wel erg lang en beleggers willen wel vorderingen zien.
    Dat duurt echter maar en dat mag Vivoryon zich aantrekken.
    Echter alles is relatief, een klein berichtje dat de vorderingen op schema liggen is genoeg om de koers weer opwaarts te krijgen.
    Dat ook dat uitblijft is niet sterk en geeft weinig zekerheid, en dat is juist het onderdeel waarop beleggers keuzes maken.
    Dat doen ze dan ook. Nu nog met kleine stapjes maar bij uitblijven nieuws worden de stapjes groter.

    Kom op Vivoryon laat zelf eens wat positiefs horen!
  14. orap 14 augustus 2023 13:38

    • orap

      Lid sinds: 28 nov 2011

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 130

      Gegeven: 0

    •    Aantal posts: 658

    het laatste bericht van 16 juli is toch duidelijk een positief signaal; het is wachten tot 1e kwartaal 2024; dus geduld hebben.
  15. forum rang 7 Kaviaar 17 augustus 2023 10:01

    • Kaviaar

      Lid sinds: 22 jan 2013

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 5391

      Gegeven: 3512

    •    Aantal posts: 14.070

    Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer

    Frank Weber, MD, current Chief Medical Officer (CMO), promoted to Chief Executive Officer (CEO) to lead Company through next stage of development with focus on upcoming VIVIAD trial readout in 1Q24
    varoglutamstat has demonstrated potential for meaningful safety and ease of use advantages over antibody-based therapies, continues to show encouraging safety data at therapeutic dose of 600 mg twice daily, a dose demonstrated to result in nearly 90% target occupancy
    Anne Doering, CFA, to assume newly created position of Chief Strategy & Investor Relations Officer (CS&IRO) to bolster continued efforts to support varoglutamstat and Vivoryon corporate goals
    Vivoryon to report first half 2023 financial results and operational progress on September 7, 2023
    Halle (Saale) / Munich, Germany, August 4, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, announced that Frank Weber, MD, Vivoryon’s Chief Medical Officer (CMO) will assume current CEO Dr. Ulrich Dauer’s responsibilities effective August 14, 2023. Dr. Weber has a long-standing history with the Company, having joined Vivoryon in 2010. He has deep knowledge of the scientific foundation of the Company and has been integral in shaping varoglutamstat’s rigorous clinical development strategy. Dr. Ulrich Dauer will support the Company through the transition period in an advisory role through the end of 2023.

    “I am honored to become the next CEO of Vivoryon and to continue to work alongside Uli and the team through this transition period. We have developed a truly differentiated and compelling small molecule for the treatment of Alzheimer’s disease, and I am excited to lead this team through varoglutamstat’s late clinical-stage development as we work tirelessly to bring this exceptional product to patients in need. I look forward to leading the Company through VIVIAD’s trial readout in the first quarter of 2024 as well as partnering with the broader management team and the Board to further support Vivoryon along its future growth path. Contrasted with currently approved products, varoglutamstat’s convenient oral administration and promising safety profile with no ARIAs has potential to be a transformative medicine that can deliver extraordinary value to patients with Alzheimer’s disease and their caregivers. As varoglutamstat approaches the final stages of its Phase 2 development, I feel confident that the Company is poised to become a leader in the field of Alzheimer’s disease treatment with our novel approach,” commented Frank Weber, MD. “I also would like to express my deep gratitude to Uli not only as the leader of Vivoryon for many years, but also as a trusted partner throughout my role as CMO.”

    Further management changes include Anne Doering, CFA, the Company’s current Head of Investor Relations, taking on the newly created position of CS&IRO effective August 14, 2023, supporting Dr. Weber. Ms. Anne Doering joined Vivoryon as Head of Investor Relations in April 2023, focusing on expanding the Company’s investor communications and network by leveraging her capital markets experience. In this newly created position, Ms. Doering will lead the development and execution of portfolio and growth strategies for the Company while remaining responsible for investor relations activities.

    “Uli’s leadership has transformed Vivoryon to become a financially stable company with clinical and operational success. Vivoryon has never been stronger and is well-positioned for the future with a clear, differentiated strategy in Alzheimer’s disease and is at the cusp of delivering extraordinary value for patients and shareholders. It is with great pleasure that we announce Frank’s designation as CEO. The Board has worked closely with Frank for several years and we believe that he will be a significant asset to the company in this new role, having been a true partner in all aspects of Vivoryon’s business in a leadership capacity. Given Frank’s extensive clinical development expertise and his integral role in varoglutamstat’s clinical development strategy, combined with his corporate strategy and financial experience resulting from numerous successful transactions throughout his tenure, we feel he is the natural choice to succeed Uli. We have full confidence that he will successfully steer Vivoryon as we approach a clinical inflection point with our upcoming VIVIAD results in the first quarter of 2024 and we anticipate a smooth and effective leadership transition,” commented Dr. Erich Platzer, Chairman of the Board. “In addition, Anne’s experience complements the new leadership team very well, broadening the Company’s visibility in the capital markets and supporting Frank through key inflection points with varoglutamstat. We welcome her on board.”

    Dr. Weber brings 30 years of experience in the pharmaceutical and life science industry. He supported InterMune (now Genentech/Roche), in particular, its launch of Esbriet in Europe, as Global Clinical Advisor. Prior to this, he served as Chief Medical Officer at Merck KGaA in Germany and Switzerland, where he contributed to several marketing authorizations and market access agreements in the EU, U.S. and Japan and also spearheaded personalized medicine, biomarker and companion diagnostics. During his career, he has also been involved in several M&A transactions as well as licensing deals. Dr. Weber started his industry career after ten years in academic clinical research and patient care in the areas of cancer, immunology, infectiology and maxillo-facial surgery. His past roles include management positions in medical affairs and clinical development at American Cyanamid (Lederle), USA and at Synthelabo (now Sanofi), France. Dr. Weber is also a board member at Zambon Biotech SA, a Swiss-based private company searching for innovative in-licensing projects for the Zambon Group. Dr. Weber is a licensed physician and received his MD in Cancer Immunology from the Medical University Cologne, Germany.

    Ms. Doering brings over 25 years of capital markets, investment and corporate biopharmaceutical industry experience. Prior to joining Vivoryon, Ms. Doering was Director of Investor Relations at BioNTech and Director of Group Strategy at Merck KGaA, where she contributed to the strategic direction of the company. Her additional corporate experience includes R&D finance and strategy at Merck & Co. On the investment front, Ms. Doering helped build the Franklin European Equity Funds franchise at Franklin Templeton, a leading global asset manager, as portfolio manager and analyst and has spent time in venture capital at Creathor Ventures in Germany. In addition, for several years Ms. Doering was a healthcare equity research analyst covering pharmaceutical companies for a number of investment banks in New York including Bear Stearns, Credit Suisse, Bank of America and Commerzbank, during which time she was instrumental in the team achieving a #1 Institutional Investor ranking. Ms. Doering holds an MBA from The Wharton School and an MA in International Studies from The Lauder Institute, both of the University of Pennsylvania. She is also a Chartered Financial Analyst (CFA) Charterholder.

    Vivoryon will hold an Extraordinary General Meeting (EGM) on Friday, September 15, 2023, in connection with the appointment of Dr. Weber and Ms. Doering to the Company’s Board as executive directors
  19. forum rang 6 Rowi62 25 augustus 2023 09:46

    • Rowi62

      Lid sinds: 27 okt 2016

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 2762

      Gegeven: 1983

    •    Aantal posts: 6.390

    Net gelezen over een Republican kandidaat voor de presidentsverkiezingen Vivek Ramaswamy:

    How populist "entrepreneur" Vivek Ramaswamy got rich:
    1. Found biotech firm with hedge fund/venture capital $
    2. Buy patent for Alzheimer's drug that had failed 4 trials, raise more $ to take to market
    3. Take company public, cash out
    4. Drug fails 5th trial, investors wiped out.
6.265 Posts
Pagina: «« 1 ... 293 294 295 296 297 ... 314 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in
VIVORYON THERAPEUTICS N.V.

Van de redactie

  1. 10 afgeprijsde aandelen van topbedrijven
  2. Met deze ETF kleurt uw portefeuille groen als de S&P 500 daalt
  3. 7 koopwaardige aandelen voor de lange termijn
  4. Dit aandeel is toegevoegd aan favorietenlijstje beleggers
  5. TA-column Nico Bakker: koopkansen bij Nvidia?
  6. Twee groeiaandelen met verdubbelpotentieel in vijf jaar
Meer artikelen